Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.66 |
| ▸ | CNR1 | P21554 | 3/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.55 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.54 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.51 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | HLCS | P50747 | 2/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30165784 | 1.00 | CNR2 (0.66) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL12989865 | 0.99 | CNR2 (0.68) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL16419858 | 0.94 | CNR2 (0.59) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL28660549 | 0.94 | CNR2 (0.59) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL29688513 | 0.94 | CNR2 (0.78) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL12582940 | 0.93 | CNR2 (0.66) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL15746589 | 0.92 | CNR1 (0.64) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL29758823 | 0.91 | CNR2 (0.64) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL29910364 | 0.90 | CNR2 (0.73) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL29700479 | 0.90 | CNR2 (0.67) | CNR2CNR1F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9943602-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150125518-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8962015-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8846053-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | SDG, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | SDG, INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | HAVCR2, IFNAR1, MSR1 | CNR2 2404/4885CNR1 1331/4885F2 2393/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | CNR2 1029/4885CNR1 1065/4885F2 2252/4885 |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | CNR2 2524/4885CNR1 1514/4885F2 2498/4885 |
| US-20150125518-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | CNR2 721/4885CNR1 464/4885F2 2636/4885 |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | CNR2 1119/4885CNR1 719/4885F2 2597/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | CNR2 1029/4885CNR1 1065/4885F2 2252/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | CNR2 604/4885CNR1 795/4885F2 1894/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | CNR2 670/4885CNR1 775/4885F2 2357/4885 |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | IAPP, IDE, INSR | CNR2 1363/4885CNR1 1436/4885F2 739/4885 |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, LIPC, FABP6 | CNR2 604/4885CNR1 795/4885F2 1894/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | CNR2 604/4885CNR1 795/4885F2 1894/4885 |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | CNR2 1119/4885CNR1 719/4885F2 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.